NASHVILLE, Tenn. / Sep 03, 2024 / Business Wire / Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, today announced that management will participate in the following three investor conferences in September in New York:
H.C. Wainwright 26th Annual Global Investment Conference (Lotte New York Palace Hotel)
September 9-11, 2024
Company will present at 8:00 a.m. ET on September 10, 2024
Lake Street 8th Annual Best Ideas Growth Conference – Big 8 (The Yale Club)
September 12, 2024
1x1 Meetings Only
Cantor 2024 Global Healthcare Conference (InterContinental New York Barclay Hotel)
September 17-19, 2024
Company will host a Fireside Chat at 2:30 p.m. ET on September 18, 2024
The Company will conduct one-on-one meetings at each conference. Investors interested in meeting with management during conferences should contact their representative at each firm to request a meeting. To listen to the audio webcast of either the H.C. Wainwright or Cantor conferences, please visit the Company’s website. The Lake Street conference will not be webcast.
About Harrow
Harrow, Inc. (Nasdaq: HROW) is a leading eyecare pharmaceutical company engaged in the discovery, development, and commercialization of innovative ophthalmic pharmaceutical products for the North American market. Harrow helps eyecare professionals preserve the gift of sight by making its portfolio of prescription and non-prescription pharmaceutical products accessible and affordable to millions of patients each year. For more information about Harrow, please visit harrow.com.
| Last Trade: | US$24.49 |
| Daily Change: | 0.90 3.82 |
| Daily Volume: | 1,016,096 |
| Market Cap: | US$871.980M |
March 24, 2025 March 17, 2025 | |
ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...
CLICK TO LEARN MORE
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MORE
